Michael Davidson/LinkedIn
Nov 23, 2025, 14:48
Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction
Michael Davidson, CEO of NewAmsterdam Pharma, posted on LinkedIn:
”Today’s standard lipid-lowering therapies focus almost exclusively on LDL-C reduction. Yet across large-scale studies, only 20–35% of patients taking them are meeting their risk-based LDL-C goals, highlighting the need for additional therapies.
Additionally, to maximize cardiovascular risk reduction, we need to address additional factors like lipoprotein(a), small LDL particles, and ApoB.
Learn how we can broaden the approach to reducing cardiovascular risk.”
Read more here.
Stay updated wth Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology